Arpida Ltd (SWX: ARPN) announced the enrolment of the first patients into the Phase II “intravenous-to-oral” switch trial with oral iclaprim in complicated Skin and Skin Structure Infections (cSSSI). Enrolment remains on track for completion in 2008. The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with a full course of intravenous (i.v.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 27th, 2008 under skin health.
Comments: none

When patches of red, flaky and itchy skin on newborn mice led rapidly to their deaths, researchers looked for the reason why. What they found was a molecular alarm system that serves as a sentinel to monitor the integrity of skin — the body’s essential protective barrier.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 27th, 2008 under skin health.
Comments: none